MOMTAS LOTION
Mometasone Furoate
30ML
Maruti Pharma Pvt. Ltd.
| Pack size | 1's |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 300.00 NPR |
Indications
MOMTAS LOTION is used for:
Allergic rhinitis, Nasal polyps, Asthma prophylaxis
Adult Dose
Nasal
Allergic rhinitis
Adult: Nasal Treatment and prophylaxis of allergic rhinitis Adults: 100 mcg (2 sprays) in each nostril once daily, increased to 200 mcg into each nostril once daily if needed. Maintenance: 50 mcg in each nostril daily.
In patients with a known seasonal allergen that precipitates nasal symptoms of seasonal allergic rhinitis, prophylaxis with Mometasone Nasal Spray is recommended 2 to 4 weeks prior to the anticipated start of the pollen season.
Nasal polyps:
100 mcg (2 sprays) in each nostril once daily; may increase to bid after 5-6 wk if needed.
Inhalation
Asthma prophylaxis:
Mild to moderate: Initially, 400 mcg once daily in the evening. Maintenance: 200 mcg once to bid.
Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.
Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid. Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.
Child Dose
Nasal
Allergic rhinitis
Child: 2-11 yr: 50 mcg (1 spray) in each nostril daily; Child: >12 yr: 100 mcg in each nostril daily.
Inhalation
Asthma prophylaxis:
Child: Mild to moderate: Initially, 400 mcg once daily. Maintenance: 200 mcg once to bid.
Severe: Initially, 400 mcg bid, then titrated to lowest effective dose once controlled.
Renal Dose
Administration
Contra Indications
Hypersensitivity, Immunosuppressed patients, Tuberculosis, Status asthmaticus or other acute asthma episode necessitating intensive measures, Known hypersensitivity to milk proteins or any other ingredients
Precautions
Respiratory tract tuberculosis, untreated fungal or bacterial infections, viral or parasitic infections, ocular herpes simplex
Nasal septum perforation, epistaxis, wheezing
Cataracts, glaucoma, increased intraocular pressure
Risk of more serious or fatal course of chickenpox and measles in susceptible individuals; avoid use in unvaccinated or immunologically unexposed children or adults
Deaths from adrenal insufficiency have occurred after abrupt withdrawal of oral steroids; taper withdrawal gradually
May retard growth in children
Immunocompromised patients
Infections of nose and pharynx, including Candida albicans
Excessive use may suppress hypothalamic-pituitary-adrenal function
During periods of stress or severe status asthmaticus, patient may require supplementary systemic corticosteroids immediately; carry warning card to that effect
Long-term administration reduces bone mineral density
Pregnancy-Lactation
Interactions
Increased risk of hypokalaemia with amphotericin B, potassium-wasting diuretics. Decreases hypoglycaemic effects of antidiabetic drugs. Increased serum levels with antifungals (imidazole). Increased risk of tendinopathies with fluoroquinolones.
Adverse Effects
Side effects of Mometasone Furoate :
>10%
Headache (26%),Viral infection (14%),Pharyngitis (12%),Epistaxis (11%)
1-10%
Cough (7%),Upper respiratory tract infection (6%),Dysmenorrhea (5%)
Frequency Not Defined
Loss of taste,Muscle soreness
Mechanism of Action
Mometasone depresses the formation, release and activity of endogenous inflammatory chemical mediators (e.g. kinins, histamine, liposomal enzymes and prostaglandin). It inhibits the margination and subsequent cell migration to the injury site, reverses vascular dilatation and permeability, resulting in decreased access of cells to the area of injury.
Note
MOMTAS 30ML LOTION manufactured by Maruti Pharma Pvt. Ltd.. Its generic name is Mometasone Furoate. MOMTAS is availble in Nepal.
Farmaco Nepal drug index information on MOMTAS LOTION is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.